Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones

Short Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in class

Related Keywords

United Kingdom ,Australia ,United States ,New Zealand ,Australian ,American ,Cameron Durrant ,Tim Morris ,Jersey Newsfile Corp ,Leukemia Research ,International Working Group Criteria ,Nasdaq ,Leukaemia Foundation ,Research Institute ,Humanigen Inc ,Australian Health ,American Journal Of Blood Research ,American Cancer Society ,Therapeutic Goods Administration ,Short Hills ,International Working Group ,Principal Investigator ,Project Orbis ,Australian Registry ,South Australian Health ,Medical Research Institute ,Retrieved July ,Blood Research ,England Journal ,Humanigen ,Implements ,Strategic ,Realignment ,Pipeline ,Resources ,Chieve ,Linical ,Ilestones ,